These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1153 related articles for article (PubMed ID: 32042148)

  • 21. Capsid-Engineering for Central Nervous System-Directed Gene Therapy with Adeno-Associated Virus Vectors.
    Macdonald J; Marx J; Büning H
    Hum Gene Ther; 2021 Oct; 32(19-20):1096-1119. PubMed ID: 34662226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming innate immune barriers that impede AAV gene therapy vectors.
    Muhuri M; Maeda Y; Ma H; Ram S; Fitzgerald KA; Tai PW; Gao G
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33393506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SUMOylation Targets Adeno-associated Virus Capsids but Mainly Restricts Transduction by Cellular Mechanisms.
    Chen Q; Njenga R; Leuchs B; Chiocca S; Kleinschmidt J; Müller M
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.
    Louis Jeune V; Joergensen JA; Hajjar RJ; Weber T
    Hum Gene Ther Methods; 2013 Apr; 24(2):59-67. PubMed ID: 23442094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.
    Costa Verdera H; Kuranda K; Mingozzi F
    Mol Ther; 2020 Mar; 28(3):723-746. PubMed ID: 31972133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer.
    Kwon I; Schaffer DV
    Pharm Res; 2008 Mar; 25(3):489-99. PubMed ID: 17763830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AAV's anatomy: roadmap for optimizing vectors for translational success.
    Mitchell AM; Nicolson SC; Warischalk JK; Samulski RJ
    Curr Gene Ther; 2010 Oct; 10(5):319-340. PubMed ID: 20712583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic Engineering of AAV Capsid Gene for Gene Therapy Application.
    Liu Y; Zhang X; Yang L
    Curr Gene Ther; 2020; 20(5):321-332. PubMed ID: 32998676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.
    Martino AT; Suzuki M; Markusic DM; Zolotukhin I; Ryals RC; Moghimi B; Ertl HC; Muruve DA; Lee B; Herzog RW
    Blood; 2011 Jun; 117(24):6459-68. PubMed ID: 21474674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Viral vector-mediated gene therapies.
    Hollinger K; Chamberlain JS
    Curr Opin Neurol; 2015 Oct; 28(5):522-7. PubMed ID: 26263476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications.
    Schön C; Biel M; Michalakis S
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):343-52. PubMed ID: 25615882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developing immunologically inert adeno-associated virus (AAV) vectors for gene therapy: possibilities and limitations.
    Selot RS; Hareendran S; Jayandharan GR
    Curr Pharm Biotechnol; 2014; 14(12):1072-82. PubMed ID: 24678652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic gene transfer to skeletal muscle using reengineered AAV vectors.
    Phillips JL; Hegge J; Wolff JA; Samulski RJ; Asokan A
    Methods Mol Biol; 2011; 709():141-51. PubMed ID: 21194026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
    Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
    J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and Validation of Small Molecules That Enhance Recombinant Adeno-associated Virus Transduction following High-Throughput Screens.
    Nicolson SC; Li C; Hirsch ML; Setola V; Samulski RJ
    J Virol; 2016 Aug; 90(16):7019-7031. PubMed ID: 27147738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of the adeno-associated virus capsid in gene transfer.
    Van Vliet KM; Blouin V; Brument N; Agbandje-McKenna M; Snyder RO
    Methods Mol Biol; 2008; 437():51-91. PubMed ID: 18369962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineering the AAV capsid to optimize vector-host-interactions.
    Büning H; Huber A; Zhang L; Meumann N; Hacker U
    Curr Opin Pharmacol; 2015 Oct; 24():94-104. PubMed ID: 26302254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CpG-depleted adeno-associated virus vectors evade immune detection.
    Faust SM; Bell P; Cutler BJ; Ashley SN; Zhu Y; Rabinowitz JE; Wilson JM
    J Clin Invest; 2013 Jul; 123(7):2994-3001. PubMed ID: 23778142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors.
    Blankinship MJ; Gregorevic P; Chamberlain JS
    Mol Ther; 2006 Feb; 13(2):241-9. PubMed ID: 16361117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19.
    Heister T; Heid I; Ackermann M; Fraefel C
    J Virol; 2002 Jul; 76(14):7163-73. PubMed ID: 12072516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.